Factors associated with 1-year outcomes and transient intraocular pressure elevation in minimally invasive glaucoma surgery using Kahook Dual Blades.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Intraocular Pressure* ; Glaucoma*/surgery; Humans ; Case-Control Studies ; Retrospective Studies ; Tonometry, Ocular

In this retrospective case-control study, we aimed to investigate the mid- to long-term outcomes and factors involved in minimally invasive glaucoma surgery using the Kahook Dual Blade. Of the 229 cases since 2018 in which the dual blades were used for glaucoma surgery at the Tenri Hospital, 133 eyes of 98 patients who followed up for more than 3 months were included. Intraocular pressure (IOP), number of drops score, and need for reoperation were evaluated on day 1 and at 1, 3, 6, 9, and 12 months postoperatively. Intraocular pressure spikes occurred in 25 patients postoperatively (18.8%), occurring at approximately 4.5 days (1-10.25). The preoperative number of eye drops used and ocular axial length were found to be associated with the occurrence of spikes (OR = 1.45, 95% CI 1.02-2.06; P = 0.025 and OR = 1.41, 95% CI 0.98-1.25; P = 0.072, respectively). At the 12-month mark, no significant relationship was found between the presence of spikes or incisional extent scores and the amount of change in IOP and number of drops scores. Patients with severe visual field impairment, high preoperative IOP and drop scores, and long ocular axial length may require more frequent follow-ups after surgery to check for spikes.
(© 2023. Springer Nature Limited.)

J Clin Med. 2022 Mar 01;11(5):. (PMID: 35268445)
Ophthalmology. 2001 Nov;108(11):1943-53. (PMID: 11713061)
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2771-2781. (PMID: 33907888)
Adv Ther. 2016 Jun;33(6):959-81. (PMID: 27138604)
Br J Ophthalmol. 2020 Aug;104(8):1137-1141. (PMID: 31704699)
Biomed Tech (Berl). 2009 Feb;54(1):14-22. (PMID: 19182869)
J Glaucoma. 2018 Oct;27(10):849-855. (PMID: 29979337)
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30. (PMID: 12049574)
Harefuah. 2014 Oct;153(10):581-5, 625. (PMID: 25518075)
Adv Ther. 2018 Sep;35(9):1460-1469. (PMID: 30078175)
Ophthalmology. 2020 Mar;127(3):333-345. (PMID: 31727428)
Exp Eye Res. 2016 Jan;142:13-8. (PMID: 25805322)
Ophthalmology. 2008 Jun;115(6):941-948.e1. (PMID: 17997485)
J Cataract Refract Surg. 2014 Aug;40(8):1263-72. (PMID: 25088623)
Sci Rep. 2021 May 21;11(1):10660. (PMID: 34021228)
Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):203-214. (PMID: 32501895)
Graefes Arch Clin Exp Ophthalmol. 2017 Aug;255(8):1643-1650. (PMID: 28528378)
Retina. 2021 Dec 1;41(12):2571-2577. (PMID: 34009183)
Clin Ophthalmol. 2019 Apr 24;13:715-721. (PMID: 31114149)
Clin Ophthalmol. 2018 May 17;12:915-923. (PMID: 29844656)
Exp Eye Res. 2006 Apr;82(4):545-57. (PMID: 16386733)
Exp Eye Res. 2009 Apr;88(4):769-75. (PMID: 19114037)
PLoS One. 2019 Oct 24;14(10):e0223439. (PMID: 31647848)
Jpn J Ophthalmol. 2018 Mar;62(2):201-208. (PMID: 29305716)
Clin Ophthalmol. 2019 Oct 15;13:2017-2024. (PMID: 31686776)
Am J Ophthalmol. 2013 Mar;155(3):524-529.e2. (PMID: 23218696)
Exp Eye Res. 2011 Feb;92(2):104-11. (PMID: 21187085)
Ophthalmology. 1999 Nov;106(11):2144-53. (PMID: 10571351)
Ophthalmol Glaucoma. 2018 Jul - Aug;1(1):75-81. (PMID: 32672636)
Ophthalmic Physiol Opt. 2018 May;38(3):266-272. (PMID: 29691920)
Clin Ophthalmol. 2019 Dec 02;13:2369-2376. (PMID: 31819362)
Graefes Arch Clin Exp Ophthalmol. 2020 Feb;258(2):387-393. (PMID: 31811364)
Adv Ther. 2019 Sep;36(9):2515-2527. (PMID: 31317390)
J Glaucoma. 2019 May;28(5):411-414. (PMID: 31048639)

Date Created: 20230914 Date Completed: 20230918 Latest Revision: 20231123

20231123

PMC10502046

10.1038/s41598-023-42575-3

37710010